东方法百泰生物技术

Beijing Dongfang Fabaitai Biotechnology is a Chinese biopharmaceutical company focused on the development and commercialization of therapeutic monoclonal antibodies for oncology. The company serves as a primary domestic vehicle for the China-Cuba biotechnology cooperation, holding a significant stake in the joint venture Biotech Pharmaceutical Co., Ltd. (BPL). Its flagship product, Taixinsheng (Nimotuzumab), is a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and was the first such therapy approved in China for nasopharyngeal carcinoma. Dongfang Fabaitai is actively expanding the clinical applications of Taixinsheng through Phase 3 trials in indications including pancreatic cancer, glioma, and esophageal cancer. The company leverages advanced mammalian cell culture and antibody humanization technologies to maintain its position in the targeted therapy market. Based in Beijing, it remains a central figure in the commercial success of collaborative biopharmaceutical projects between China and Cuba.